BioWorld by Clarivate Examines Impact of Emerging Medicines on Obesity


BioWorld™ published by Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, examines the impact of emerging obesity medicines in a new three-part series, The Rise of Obesity. The special coverage offers in-depth analysis of how the anticipated multibillion-dollar market potential for obesity medications in the coming years will impact biopharma, insurance companies and a patient population in need of safer options.

The increasing prevalence of obesity across the world is driving interest among investors to be a part of a movement that is poised to change the health care paradigm. Emerging medicines including glucagon-like peptide 1 (GLP-1) receptor agonists and drugs with other mechanisms of action are increasingly shown to have benefits beyond weight loss.

Over $1 billion of investment is anticipated in obesity through licensing or M&As in 2023,1 with the overall market expected to climb upwards of $50 billion in the coming years. The result of such growth could include significant savings in treating obese and overweight conditions, as well as the comorbidities associated with them. Novo Nordisk recently reported sales of Wegovy totalling $1.7 billion for the first half of 2023, up 367% over the prior year.2 Sales of Ozempic, a lower-dose version of semaglutide, are up 58% year over year.3 The significant rise in sales reinforces the meteoric rise of obesity drugs – profits of which can help drive drug development to further benefit patients and business stakeholders alike.

Karen Carey, BioWorld Managing Editor and Senior Analyst, explores the challenges and the opportunity of advancing obesity medications, in three in-depth features, including:

Lynn Yoffee, Publisher, BioWorld, said: “Drug-induced weight loss has finally matured into a viable therapeutic option. But the reality of drug development is not just proof that they work. There must be a way to bring expensive drugs to patient populations, which is why BioWorld examined drugmakers’ efforts to obtain reimbursement – tantamount to treating most patients – and the behind-the-scenes dealmaking and investments to broaden access. The BioWorld special report highlights the vast new market for drugs for obesity that will have major impacts on overall health since reducing weight is associated with reducing co-morbidities and costs associated with down-the-road diseases.”

For more exclusive in-depth coverage of obesity and metabolic health on BioWorld, visit here.

Join the conversation and mention BioWorld on Twitter and LinkedIn as well as Clarivate for Life Sciences & Healthcare on Twitter and LinkedIn.


BioWorld by Clarivate Rethinks Obesity in New Special Investigation, Finding Fitness May Be More Linked to Health than Weight


BioWorld™ published by Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, explores how difficult scientific detachment can be for health topics that have large cultural components- such as obesity. After many years of research and development, drug-induced weight loss has matured into a viable therapeutic option. Special investigation from BioWorld provides in-depth analysis of the latest advances in metabolic health, how fitness may play a role in these shifts and how scientists’ perceptions of the obesity epidemic may shift.

According to the World Obesity Federation, one billion people globally will be living with obesity by 2030. With medical researchers’ laser focus on finding solutions to address the obesity epidemic, excitement is finally building around the next generation of drugs developed to help adults shed excess weight. These new classes of drugs offer promising results and may provide an alternative solution to weight loss other than invasive procedures such as bariatric surgery. While new weight loss drugs are an extraordinary advance in medicine and will likely become some of the most prescribed of all medications in the upcoming years, how will perceptions in the medical community around the role of fitness in weight loss and overall health evolve?

Following deep analysis of the latest studies on weight loss, metabolic health and fitness, BioWorld Science Managing Editor, Anette Breindl, discusses:

  • How difficult scientific detachment can be for health topics that have large cultural components. Heated debates continue around the discrepancies between individuals with Body Mass Index (BMI) in the “overweight” range, often associated with the greatest longevity, and individuals in the so-called “Class I obesity” category, who often live as long as those with a “normal” BMI.
  • How weight loss is blind to the behavioral differences between brown and white fats. Weight may be a poor proxy for health as fat cells are distributed throughout the body, and the details of where they are and what they are doing matter a great deal.
  • The effects of GLP-1R agonists, also called incretin mimetics, which go far beyond weight loss, and the question of whether weight loss is causal to their effects.
  • How new methods are enabling a molecular understanding of exercise, which may be much more important to health than weight is.

Lynn Yoffee, Publisher, BioWorld said: “Drug-induced weight loss has finally matured into a viable therapeutic option for patients. At the same time, there are longstanding concerns that the health effects of weight might be overrated. Can a person still be considered fit and healthy despite being over what is considered a normal weight? BioWorld Science Managing Editor Anette Breindl has reviewed the latest research around these challenges and raised several complicated red flags, just as millions of people are desperately hoping that the new weight loss pills are the answer in the quest to be healthy.”